RO9021 manufacturers
- RO9021
-
- $40.00
-
2026-07-27
- CAS:1446790-62-0
- Purity: 99.90%
- Supply Ability: 10g
|
| Product Name: | RO9021 | | Synonyms: | RO9021;RO-0921;RO 0921;CS-2533;6-((1R,2S)-2-amino-cyclohexylamino)-4-(5,6-dimethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide;3-Pyridazinecarboxamide, 6-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[(5,6-dimethyl-2-pyridinyl)amino]-;RO-9021,Spleen tyrosine kinase,RO 9021,Inhibitor,inhibit,RO9021,Syk;6-(((1R,2S)-2-Aminocyclohexyl)amino)-4-((5,6-dimethylpyridin-2-yl)amino)pyridazine-3-carboxamide;RO-9021 (RO 9021 | | CAS: | 1446790-62-0 | | MF: | C18H25N7O | | MW: | 355.44 | | EINECS: | | | Product Categories: | | | Mol File: | 1446790-62-0.mol |  |
| | RO9021 Chemical Properties |
| Boiling point | 618.5±55.0 °C(Predicted) | | density | 1.288±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | A solid | | pka | 14.25±0.50(Predicted) | | color | White to off-white |
| | RO9021 Usage And Synthesis |
| Uses | RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of SYK, with an average IC50 of 5.6 nM. | | Biological Activity | ro9021 is a syk inhibitor.spleen tyrosine kinase (syk) is identified as a critical integrator of intracellular signals regulated by activated immunoreceptors, such as fc receptors and bcell receptors (bcr), which are of great importantance for the function and development of lymphoid cells. | | in vitro | previous study found that in addition to the suppression of bcell receptor signaling in human peripheral blood mononuclear cells and whole blood, fcγr signaling in human monocytes, and fc r signaling in human mast cells, ro9021 could also block the in vitro osteoclastogenesis from mouse bone marrow macrophages. moreover, the toll-like receptor 9 signaling in human bcells could be blocked by ro9021, leading to the decreased levels of plasmablasts, immunoglobulin (ig) g and igm upon b-cell differentiation. in addition, ro9021 could also potently inhibit type i interferon production by human plasmacytoid dendritic cells (pdc) via tlr9 activation, and such effect was found to be specific to tlr9 since ro9021 did not show inhibitary effect on tlr4- or jak-stat-mediated signaling [1]. | | in vivo | animal study showed that the oral administration of ro9021could significanly inhibit the arthritis progression in the mcia model, with well observed pharmacokinetics-pharmacodynamic correlation [1]. | | IC 50 | 5.6 nm | | references | [1] liao c, et al. selective inhibition of spleen tyrosine kinase (syk) with a novel orally bioavailable small molecule inhibitor, ro9021, impinges on various innate and adaptive immune responses: implications for syk inhibitors in autoimmune disease therapy. arthritis res ther. 2013 oct 4;15(5):r146. |
| | RO9021 Preparation Products And Raw materials |
|